TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00115037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparer for 16 weeks in phase 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management (MM)
Description: Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medication Management (MM)
Description: Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Description: 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Combined Behavioral Intervention (CBI)
Description: 45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
Study: NCT01733485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 500 mg/8 h for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: 25 mg/8 h for 5 days
Study: NCT00090584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: 4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: 4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training
Description: Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
Study: NCT03151395

Intervention type: OTHER
Group type: OTHER
Intervention: Sputum and blood sampling
Description: Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
Study: NCT04245202

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNCOT
Description: The patient will receive a high flow nasal of humidified oxygen, set between 2 to 25 l/min. The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: St-FMOT
Description: The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
Study: NCT02631070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01432964

Intervention type: PROCEDURE
Intervention: Orbital revision surgery
Description: Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
Study: NCT01540136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
Study: NCT01982396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC Twice Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC Once Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC Twice Daily
Study: NCT01257139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual-agent therapy or docetaxel alone or best supportive care
Description: ARM B: (245 patients)~Treatment if the SGS screening test is negative:~* non epidermoid tumor:~* Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.~* epidermoid tumor:~* Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management.
Study: NCT04094701

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group Regimen
Description: Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid reduced regimen
Description: Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
Study: NCT03121534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for \>4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
Study: NCT02374593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT04453501

Intervention type: DRUG
Intervention: favorable outcome
Description: Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
Study: NCT00706784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
Description: Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
Study: NCT01776684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
Study: NCT02136498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Standard 12 week course of varenicline, provided in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Standard 12 week course of varenicline, provided in both arms

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-help
Description: Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral self-help
Description: Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyMAP (My Mobile Advice Program)
Description: Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
Study: NCT03244241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec 100 UNT/ML [Tresiba]
Description: Basal-bolus insulin regime
Study: NCT00678990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of islets with heparin coating
Description: Transplantation of islets with heparin coating
Study: NCT01990820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Relieva Balloon Sinuplasty
Description: A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenoidectomy + Maxillary Sinus Irrigation
Description: A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home.
Study: NCT01425632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU-284
Description: TAU-284 Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU-284
Description: TAU-284 High

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02963688

Intervention type: GENETIC
Intervention: Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform
Description: BRCA1,2 Germline /Somatic mutation test
Study: NCT05765188

Intervention type: OTHER
Intervention: loop electrosurgical excision procedure
Description: A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.

Intervention type: OTHER
Intervention: loop electrosurgical excision procedure
Description: A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
Study: NCT04055168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6615
Description: AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6615
Description: AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6615
Description: AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6615
Description: AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6615
Description: AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
Study: NCT03051490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: porcine PERT
Description: oral, enterically-coated, pig-derived, pancreatic enzyme replacement
Study: NCT00110760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Description: S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Peel
Description: Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
Study: NCT04380818

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: 200 mg/12h for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: 200 mg/12h for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir/lopinavir
Description: 400/100 mg/12h for 7-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir/lopinavir
Description: 400/100 mg/12h for 7-10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Injection [Actemra]
Description: 600 mg/day for 1-2 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection [Actemra]
Description: 600 mg/day for 1-2 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg/24h for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg/24h for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroids (methylprednisolone/dexamethasone/prednisone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Corticosteroids (methylprednisolone/dexamethasone/prednisone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen supply
Description: Oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen supply
Description: Oxygen
Study: NCT01009047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended release (ER)
Description: Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
Study: NCT02500485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824, SP2086
Description: One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
Study: NCT03137602

Intervention type: DEVICE
Group type: OTHER
Intervention: ATOMIC mobile app
Description: (a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
Study: NCT00651443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galiximab
Description: Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
Study: NCT04596787

Intervention type: PROCEDURE
Intervention: Bilateral Thoracic paravertebral block
Description: The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).

Intervention type: PROCEDURE
Intervention: Bilateral Thoracic paravertebral block
Description: The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
Study: NCT02443103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanabenz acetate
Study: NCT01458990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20mg PO BID for 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20mg PO BID for 20 days
Study: NCT04398784

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Freeze Dried Blueberry Powder - 71717
Description: Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Freeze Dried Blueberry Powder - 71717
Description: Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: USHBC Blueberry Placebo Formula #114
Description: Blueberry flavor- and color-matched placebo powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: USHBC Blueberry Placebo Formula #114
Description: Blueberry flavor- and color-matched placebo powder.